News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, an experimental virus-based therapy that Mustang Bio is developing for…

The microenvironment of ovarian cancer tumors actively suppress the work of immune T-cells by blocking their energy supply, a study reports. These findings have implications…

A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…

The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…

Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…

Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…

Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab…

A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…

The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for…